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Abstract
Background: Depression is often associated with rapid changes in mood and quality of life that persist for a period of 2 weeks.
Despite medical innovations, there are problems in the provision of care. Long waiting times for treatment and high recurrence
rates of depression cause enormous costs for health care systems. At the same time, comprehensive limitations in physical,
psychological, and social dimensions are observed for patients with depression, which significantly reduce their quality of life.
In addition to patient-specific limitations, undersupply and inappropriate health care have been determined. For this reason, new
forms of care are discussed. Smartphone-based therapy is considered to have great potential due to its reach and easy accessibility.
Low socioeconomic groups, which are always difficult to reach for public health interventions, can now be accessed due to the
high dispersion of smartphones. There is still little information about the impact and mechanisms of smartphone-based therapy
on depression. In a systematic literature review, the health implications of smartphone-based therapy were presented in comparison
with standard care.
Objective: The objective of this review was to identify and summarize the existing evidence regarding smartphone-based
cognitive behavioral therapy for patients with depression and to present the health implications of smartphone-based cognitive
behavioral therapy of considered endpoints.
Methods: A systematic literature review was conducted to identify relevant studies by means of inclusion and exclusion criteria.
For this purpose, the PubMed and Psyndex databases were systematically searched using a search syntax. The endpoints of
depressive symptoms, depression-related anxiety, self-efficacy or self-esteem, and quality of life were analyzed. Identified studies
were evaluated for study quality and risk of bias. After applying the inclusion and exclusion criteria, 8 studies were identified.
Results: The studies examined in this review reported contradictory results regarding the investigated endpoints. In addition,
due to clinical and methodological heterogeneity, it was difficult to derive evident results. All included studies reported effects
on depressive symptoms. The other investigated endpoints were only reported by isolated studies. Only 50% (4/8) of the studies
reported effects on depression-related anxiety, self-efficacy or self-esteem, and quality of life.
Conclusions: No clear implications of smartphone-based cognitive behavioral therapy could be established. Evidence for the
treatment of depression using smartphone-based cognitive behavioral therapy is limited. Additional research projects are needed
to demonstrate the effects of smartphone-based cognitive behavioral therapy in the context of evidence-based medicine and to
enable its translation into standard care. Participatory technology development might help to address current problems in mobile
health intervention studies.
(JMIR Mhealth Uhealth 2021;9(2):e24703) doi: 10.2196/24703
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Introduction
Background
Depression can affect mental and physical health. It is estimated
that nearly 322 million people worldwide have depression, and
the World Health Organization (WHO) has stated that
depression is the single largest factor contributing to global
disability [1]. Recently, findings from the Global Burden of
Disease study stated that the incidence of depression has
increased by approximately 50% in 2017 compared with that
in 1990 [2]. Depression is equally prevalent in high-income
countries and middle- to low-income countries [3]. In addition,
the European Health Interview showed that the European
average accounts for approximately 6.6% of people with
depression [4]. Due to the widespread prevalence of depression
and its rising burden, the social and health policy significance
of mental illnesses is increasing [5]. Therefore, depression is a
major global public health domain of the 21st century, and its
importance is increasing.
Depression is associated with changes in mood and quality of
life that persist for a period of 2 weeks [6]. Furthermore, a
decline in activity, loss of appetite, or prolonged fatigue is
observable. In addition, depression is associated with higher
mortality rates, which can be explained by depression-related
suicide and an unhealthy lifestyle that can cause diabetes or
cardiovascular diseases. Suicide is a major cause of injury and
death worldwide [7]. Approximately 15% of patients with
depression face suicidal thoughts [8].
In addition to the rising numbers and the increasing burden of
disease, mental illnesses have major economic influences. The
Federal Statistical Office of Germany reported that in 2019,
direct costs of approximately 8.7 billion Euros (US $ 10.5
billion) were caused by depression in Germany. It was estimated
that 4.6 billion Euros (US $ 5.5 billion) were spent on the
inpatient sector and 3.3 billion Euros (US $ 4.0 billion) were
spent on the outpatient sector. This corresponds to approximately
2.6% of the total costs in the health care system [9]. In addition,
approximately 42% of early retirements were found to be
associated with mental disorders. A health report published by
the German insurance company Deutsche Angestellten
Krankenkasse ranked mental disorders third in 2019, causing
15.2% of all sick leave days in Germany annually. Only
respiratory and musculoskeletal disorders have caused more
sick leave days than mental disorders [10,11].
In the past, people with a diagnosis of mental illness faced social
consequences such as marginalization, stigmatization, and
isolation [12]. However, in recent years, public awareness has
increased, and patients with depression should no longer feel
the need to conceal their diagnosis. A correct diagnostic
classification by the general practitioner and early assessment
of treatment needs can significantly contribute to less
concealment of diagnoses and public awareness [13].
Even today, people with depression face different barriers to
health care access. In contrast to chronic diseases with no
reversibility, depression is a treatable disease. Only 25% of
depressed patients receive accurate care, and in Germany,
approximately 50% are not provided with medical
guidelines-oriented care [14]. There are both patient-level and
system-level reasons for this undersupply and existing barriers.
Patient-level barriers are associated with time, transportation
constraints, or a considerable cost. System-level barriers include
long waiting lists and a dearth of therapists and doctors,
especially in rural areas and low-income countries [15,16].
High-income countries can provide, on average, 72 mental
health workers per 100,000 individuals, whereas low-income
countries can only provide approximately 2 mental health
workers per 100,000 individuals [7].
To overcome these barriers, we need innovative ways to reduce
waiting times and increase professional treatment by mental
health workers. Due to the increasing use of information and
communication technologies, mobile health (mHealth) is
considered to have great potential in the health care sector.
Especially for rural care concepts, mHealth is a promising tool
to improve care in structurally weak areas. Here, the
cross-sectoral and interprofessional approach is particularly
suitable, as it can lead to a reduction in the care interruptions
between outpatient and inpatient sectors [17].
Comparison of e-mental health treatments with traditional
face-to-face treatments suggests that technology is not
predominantly accepted by patients, although it may still provide
solutions to address the patient-level and system-level barriers
[18]. Access issues can easily be mitigated using technological
innovations. Several studies have demonstrated that telemedicine
can be used for remote treatments [19,20]. First-wave
technology-based movements such as internet-based cognitive
behavioral therapy (CBT) proved their potential in different
meta-analyses, which demonstrated both their safety and
effectiveness [21,22].
The promising results of treating patients through distance have
resulted in considerable interest in transferring internet-based
and computerized techniques to smartphone apps. The crucial
factor of smartphone-based apps can be seen in their tremendous
reach. Patients can also receive therapy whenever they need it
most without taking an appointment with their therapist, which
often results in long waiting times with possible aggravation of
symptoms [23]. Currently, thousands of mental health apps are
available in the market, and these apps are designed for a brief
frequent use throughout the day [24]. Considering how fast
mental health apps are developed and implemented, it is
important to address the challenges that these developments
yield. We will face 3 major challenges in the future: (1) issues
of low engagement with digital mental health tools, (2) lack of
sufficient evidence, and (3) poor understanding related to
security issues among target groups [25].
There is a lack of evidence for efficacy of smartphone-based
interventions, which is essential for integrating new provisions
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into future health care. Although hundreds of mental health
apps are available on unregulated app stores, there are only a
few proof-of-concept studies and small-scale randomized
controlled trials (RCTs) that evaluate the effectiveness of
smartphone-based CBTs for depression [26]. Consequently, it
is critical to ensure that patients and clinicians have enough
information to understand evidence-based digital treatments for
depression. Recent meta-analyses have documented positive
effects on diabetes [27] and anxiety [28]; however, these effects
still need to be measured for depression.
Objectives
Therefore, the aim of this study was to close this existing
research desideratum. A systematic review was conducted to
examine the effects of smartphone-based CBTs for the treatment
of depression. Therefore, the leading research question was as
follows: Are smartphone-based CBTs effective for treating




The used literature was determined by a systematic search. A
systematic search was conducted in the PubMed and Psyndex
databases. Relevant articles on smartphone-based therapy and
depression were collected and evaluated. The searched terms
were extended by relevant keywords of the articles found and
supplemented by Medical Subject Headings (MeSH). Three
generic terms were identified for which related terms were
collected in English (Table 1). To obtain more results, the words
were connected using the Boolean operators AND and OR. If
the identified articles appeared to be relevant, the summaries
and available full texts were read. Further articles were found
by viewing the source references in the articles read.
Table 1. Search matrix.
Search termsTopic
Depression (MeSHa); depress; major depression; depressive disorder (MeSH); depressive disorder,
major (MeSH); depressive episode; unipolar depression
Depression
Cognitive therapy; behavior therapy (MeSH); cognitive behavioral therapy (MeSH); acceptance and
commitment therapy (MeSH), mindfulness
Cognitive behavioral therapy
Smartphone (MeSH); computers, handheld (MeSH); mHealth; mobile health; smartphone-delivered
therapy; smartphone-based therapy; internet-based interventions (MeSH); mobile applications (MeSH)
Smartphone-based interventions
aMeSH: Medical Subject Headings.
The Population, Intervention, Comparison, Outcome,
Study Search Strategy
Inclusion and exclusion criteria were developed a priori for the
systematic review. For this purpose, the PICOS (population,
intervention, comparison, outcome, study) search strategy was
used in the context of evidence-based medicine [26,29]. The
search strategy was based on population, intervention,
comparison, outcome, and study type.
Population
Studies were included if they dealt with people with mild to
moderate depression or depressive symptoms. Furthermore, the
study participants needed to be aged at least 18 years.
Studies were excluded if they dealt with subpopulations such
as children or minority groups (refugees or only specific ethnic
communities). Furthermore, studies were excluded when they
assessed depression as a comorbidity of other relevant diseases
(eg, chronic backpain, diabetes, and cancer). In addition, studies
with treatment of other forms of depression such as postpartum
depression, severe courses of depression with psychotic events,
and schizophrenia were excluded.
Intervention
Studies that focused solely on the provision of CBT via
smartphones or tablets or an additional treatment via
smartphones or tablets in combination with treatment as usual
were included. It was mandatory that the therapy provision be
delivered by smartphone or tablet apps.
On the contrary, studies were excluded if they used other therapy
delivery formats than smartphone or tablet apps. Studies that
merely provided telephone support were excluded. As the aim
of this study was to determine the effectiveness of
smartphone-delivered therapy formats, computerized therapy
formats were excluded. Web-based apps with no smartphone
or tablet involvement were also excluded.
Comparison
To include studies in the systematic review, a control group
(CG) needed to be present. The CG can be treated as usual, an
active control comparison (eg, other treatment apps), or inactive
control comparison. Studies that did not provide a CG were
excluded.
Outcomes
This systematic review assessed clinical outcome points, which
are associated with depression. The following clinical outcomes
were assessed: depressive symptoms, depression-related anxiety,
self-efficacy or self-esteem, and quality of life. Studies with the
abovementioned outcomes as primary or secondary outcomes
were included. If the study investigated one of the mentioned
endpoints, it was included in the review. Studies that did not
consider the investigated endpoints or did not report results
were excluded.
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To provide the highest degree of evidence, RCTs were
considered relevant to analyze the stated hypothesis.
Studies that that had other study designs or lacked a CG were
excluded even if they were described as an RCT. Furthermore,
owing to the large number of studies conducted in this field,
the time interval was limited to consider the most relevant
studies. Studies conducted before 2015, indicating a time
interval of the last 5 years, were excluded. Studies published in
German or English were included.
After a search syntax was developed using the search matrix
and the appropriate MeSH terms as part of the systematic
literature search, articles were identified in PubMed and Psyndex
(Multimedia Appendix 1). The search was last updated in May
2020. The inclusion and exclusion criteria were applied in a
2-stage process. First, the titles and abstracts of the studies were
reviewed using the inclusion and exclusion criteria. Duplicates
and studies that did not meet the inclusion criteria were
excluded. If the studies appeared adequate or an assessment
based on the title and abstract was not possible, the full texts
were read.
In the second step, the inclusion and exclusion criteria were
applied again to the full texts. The full texts that did not meet
the inclusion criteria were excluded. In addition to the systematic
database search, a hand search was carried out in which further
relevant studies were identified according to the inclusion and
exclusion criteria. The studies identified by hand search also
underwent a 2-stage process.
Quality Assessment
The publications included in the qualitative synthesis were
assessed for quality. The instrument described by Hailey et al
[30] was used for the quality assessment, which was extended
by the method described by Polisena et al [31]. Their approach
to the appraisal of study quality relies on the summation of 2
scales dealing with study designs and study performance
(Textbox 1 [31]). The authors state that both scales are ordinal,
as for each of the 5 study performance attributes, it is
hypothesized that they have the same impact on the quality of
the study. The scale for study design is also ordinal and values
the increasing confidence in the different designs and their
relevance for decision making.
Hailey et al [30] distinguished 4 different study designs for
quality assessment, which were assigned different scores. RCTs
with at least 50 participants per study arm received the highest
score. Retrospective, nonrandomized studies received the least
number of points. Polisena et al [31] further differentiated the
RCTs. Here, half a point was deducted if the randomization was
not described correctly or if blinding was not performed or
described.
Textbox 1. Instrument to assess the quality of the included studies.
Study category:
• Study design
• Big randomized controlled trial (RCT; ≥50 participants each intervention arm): 5 points
• Small RCT (<50 participants each intervention arm): 3 points
• Prospective nonrandomized trial: 2 points
• Retrospective nonrandomized trial: 1 point
• If RCT (half a point is deducted if the information is missing)
• Description of randomization
• Implementation of blinding
• Description of blinding
• Study performance (0=no information, 1=information limited, 2=information satisfactory)
• Patient selection
• Description of the intervention
• Specification and analysis of study (intention-to-treat)
• Patient disposal
• Outcomes reported
• Resulting quality categories
• 11.5-15.0 points: high quality (A)
• 9.5-11.0 points: good quality (B)
• 7.5-9.0 points: fair to good quality (C)
• 5.5-7.0 points: poor to fair quality (D)
• 1.0-5.0 points: poor quality (E)
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A total of 5 study performance attributes were evaluated in the
studies. Patient selection, description of the intervention,
specification of the analysis, patient dropouts, and reported
outcomes were considered. Two points were given when the
information was sufficiently presented. A lack of information
was rated with zero points. This system allowed to build a score
to categorize the studies in terms of quality. The maximum
score was 15 points for a study. Studies that achieved a
minimum score of 11.5 points were classified in category A,
which is the highest quality category. Scores between 9.5 and
11 points were of good quality and corresponded to category
B. Quality categories of classes C to E (score below 9) showed
fair to poor quality. These studies have considerable limitations
that need to be considered when interpreting the results [30].
Risk of Bias Assessment
Although the terms bias and quality are often used as
synonymous concepts to evaluate included studies in the
systematic reviews, the Cochrane Handbook distinguishes
between those terms for the following reasons. First, the key
aim of a review is to consider the extent to which the results of
the included studies should be considered. Second, a study may
have been performed with the highest possible standards but
still have an important risk of bias. Third, the risk of bias
assessment can be instrumental in overcoming the ambiguity
between quality of reporting and the quality of underlying
research. Finally, some markers of quality in medical research
(eg, ethical approval or performing sample size calculations)
are unlikely to have implications for the risk of bias [32].
Therefore, it is necessary to additionally perform a risk of bias
assessment, although the quality assessment and the risk of bias
assessment might have overlapping issues (eg, evaluation of
randomization).
In this systematic review, the risk of bias assessment was used
to evaluate the sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome
assessment, and assessment of outcome data. The Cochrane
Handbook for Systematic Reviews of Intervention (Version
5.1.0) was used as a basis for decision making, and the risk of
bias assessment was conducted using Review Manager 5.3.
(Cochrane Collaboration). By systematically screening the
included studies for different biases, either low risk, unclear
risk, or high risk evaluations were made.
Results
Overview
A total of 8 studies were included in this systematic review.
The process of study selection is further described in Figure 1.
After the search syntax was developed and entered in PubMed
and Psyndex, 580 studies were identified. A total of 302 records
were identified via PubMed, and 277 records were found in
Psyndex. One additional record was identified by hand search,
systematically reviewing the references of other studies. After
duplicates were removed, 450 records were eligible for the first
screening. The first screening was done by checking the abstract
and title of the studies and evaluating them for suitability. A
total of 394 records were excluded, resulting in 56 studies that
were included for full-text assessment. From these 56 studies,
48 studies were excluded for different reasons. The main reason
for exclusion of studies was an inappropriate intervention (22/48,
46%). This was followed by study protocols (12/48, 25%), an
inappropriate population (7/48, 15%), and inappropriate study
design (6/48, 13%). One study reported inappropriate outcomes.
The following sections will descriptively present and compare
study and patient characteristics at baseline. Subsequently, the
studies were analyzed regarding the considered endpoints,
namely, depressive symptoms, depression-related anxiety,
self-efficacy or self-esteem, and quality of life. The results of
the systematic review are presented in Table 2. Multimedia
Appendix 2 [16,33-39] presents an overview of the patient
characteristics. The results of the regarded endpoints are shown
in Multimedia Appendix 3 [16,33-39]. The patient characteristics
are presented in Multimedia Appendix 2.
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Figure 1. Process of study selection.
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bCES-D: Center for Epidemiologic Studies Depression Scale.
cCBT: cognitive behavioral therapy.
dGAD: Generalized Anxiety Disorder.
eSWLS: Satisfaction with Life Scale.
fNGSE: New General Self-Efficacy Scale.
gMSPSS: Multidimensional Scale of Perceived Social Support.
hPHQ: Patient Health Questionnaire.
iBDI: Beck Depression Inventory.
jBAI: Beck Anxiety Inventory.
kQOLI: Quality of Life Inventory.
lAAQ-II: Acceptance and Action Questionnaire.
mSDS: Sheehan Disability Scale.
nWEMWBS: Warwick-Edinburgh Mental Well-being Scale.
oESAS-R: Emotional Self-Awareness Scale-Revised.
pCSES: Coping Self-Efficacy Scale.
qMHLQ: Mental Health Literacy Questionnaire.
rDAS: Dysfunctional Attitude Scale.
sSTAI: Stat-Trait Anxiety Inventory.
tRSES: Rosenberg Self-Esteem Scale.
uQOL: Quality of Life.
vWHOQOL: World Health Quality of Life.
wURICA: University of Rhode Island Change Assessment Scale.
xCSQ: Client Satisfaction Questionnaire.
yTAU: treatment as usual.
zSUS: System Usability Scale.
Description of Study Characteristics
The selected studies were compared in terms of the country of
intervention, number of cases, investigation period, and source
of funding. Interventions were also presented according to the
endpoints, their applied instruments, and the technology used.
Finally, the quality of the studies was assessed.
The implementation of the included studies was conducted in
different regions of the world. Most of the studies (4/8, 50%)
have been conducted in North America. All studies were
performed in the United States [16,33-35]. Two studies have
been conducted in Northern Europe, with 1 study completed in
Germany [36] and 1 in Sweden [34,37]. Two studies evaluated
the effectiveness of smartphone-based therapy in South Korea
[38] and Australia [39].
The majority of studies (5/8, 63%) reported state funding. Of
the 4 identified studies conducted in the United States, 3 were
financed by the National Institute of Mental Health [16,33,34].
Two studies did not provide information on research funding
[36,39], and 1 study was funded by private donations [35].
The evaluation periods ranged from 3 weeks in the study by
Hur et al [38] to 24 weeks in the study by Ly et al [37]. In these
evaluation periods, the follow-up assessment was included.
Three studies had a shorter or equal evaluation period of 1 month
[36,38,39], and in 4 studies, the period was shorter than 3
months [16,33-35].
In total, 1534 patients were evaluated by the 8 included studies.
The range of participant numbers was considerably different
and varied from 30 to 626 (mean 341, SD 206.2; median 432),
when the intervention group (IG) and CG were considered. All
studies differentiated between a CG and IG. The number of IGs
and CGs differed between the studies. Three studies compared
an IG with a CG [36-38]. In addition, 4 studies had more than
1 IG [16,34,35,39], and 1 study was designed with 2 CGs [33].
The number of participants in the IG varied from 20 to 420
(mean 223, SD 145; median 268). Furthermore, the number of
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participants in the CG was considerably lower, ranging from
10 to 206 (mean 118, SD 62.8; median 164).
Although all studies measured depression-related symptoms as
outcomes, the instruments to assess the symptoms were
different. Patient Health Questionnaire (PHQ-9) and Beck
Depression Inventory-II (BDI-II) were the most common
instruments. Five studies used the PHQ-9 to assess
depression-related symptoms [16,34,36,37,39]. Only Dahne et
al [33] used the PHQ-8 to assess symptoms. The reason for
using the eighth version of the PHQ instead of the ninth was
not further explained by the authors. Three studies measured
depression symptoms using the BDI-II [33,37,38], and 1 study
evaluated the symptoms by using the Center for Epidemiologic
Studies Depression Scale [35].
Depression-related anxiety was measured in 4 studies
[16,35,37,38]. Two studies used the Generalized Anxiety
Disorder (7-item) Scale [35,39], and 1 study used the State-Trait
Anxiety Inventory-X2 [38] and the Beck Anxiety Inventory
tools [37].
Self-esteem or self-efficacy was measured differently by 4
studies. Two studies used the Rosenberg Self-Esteem Scale
(RSES) to assess self-esteem [36,38]. One study evaluated this
outcome using the New General Self-Efficacy Scale [35] and
the Coping Self-Efficacy Scale [39]. Both scales had good
Cronbach α values between .89 and .96.
Finally, quality of life was only measured in 2 studies. Lüdtke
et al [36] used the WHO Quality of Life survey
(WHOQOL-BREF), and Ly et al [37] used the Quality-of-Life
Inventory. Other measures that were conducted by different
studies were client satisfaction, app usability, daily functioning,
and psychological flexibility.
The CG, with whom the IG was compared, was considerably
different between the studies. Four studies provided a waitlist
CG, which provided any form of treatment [34-36,39]. Other
treatment strategies (eg, medication, psychotherapy, or coaching)
were also allowed. Two studies used an inactive CG by
providing health tips [13,16] or asking patients to complete a
mood charting app [38]. Ly et al [37] compared IG with 10
face-to-face behavioral activation sessions, indicating an active
CG. Patients were supported by therapists, and a treatment that
resulted in giving homework and setting individualized aims
was also done. Finally, the study by Dahne et al [33] was the
only study with 2 CGs. One CG was inactive, providing
treatment as usual, and the other CG was active, giving patients
access to the CBT app MoodKit, which included thought
checking, mood tracking, journaling, and activity scheduling.
The interventions performed varied between the studies. Four
studies had more than 1 IG, comparing different smartphone
apps with each other [16,34,35,39]. Often, a CBT app was
compared with a different smartphone-based therapy approach.
For example, Arean et al [16] compared the cognitive training
app EVO with an evidence-based psychotherapy app iPST,
which is a problem-based therapy approach managing mood in
7 steps. Similar approaches were conducted by Roepke et al
[35] and Stiles-Shields et al [34], which compared either a CBT
app with a self-esteem acceptance app or behavioral activation
app strategies with cognitive restructuring app therapies. The
study by Bakker et al [39] was the only study with 3 IGs. The
authors compared the self-monitoring app MoodPrism; a CBT
recommendation app MoodKit, which suggested different
strategies depending on the reported moods and anxious
feelings; and the CBT app MoodKit. In contrast, Ly et al [37]
applied smartphone-based apps as an additional component to
psychotherapy using apps between psychotherapy sessions. Hur
et al [38] applied a scenario-based app approach combined with
a 3-step quiz in which cognitive distortions were identified and
resolved with decatastrophizing approaches, similar to cognitive
restructuring. In contrast to other studies, Dahne et al [33]
provided a self-help behavioral activation app to treat patients.
This self-help approach, which should help patients in their
daily routine by providing access to cognitive strategies such
as mindfulness-based and social competence skill exercises,
was also used by Lüdtke et al [36].
The quality of the identified studies was good to very good
(mean 11.43 points, SD 2,16; median 12 points). A total of 5
studies (approximately 63%) were assessed with the highest
quality and were categorized as A. One study (approximately
12%) was evaluated with category B, and 2 studies
(approximately 25%) were labeled with C. No study could reach
the maximum score of 15 points. This may be due to difficulties
in blinding in mHealth studies. In contrast to pharmaceutical
studies with placebo controls, blinding is difficult to guarantee
in mHealth studies. All studies were RCTs. Of these studies, 3
had more than 50 participants in the IG [16,35,39]. The other
5 studies presented less than 50 participants in the IG
[33,34,36-38]. Detailed measurements that were performed
concerning the study design or study performance are presented
in Multimedia Appendix 4.
The performed risk of bias assessment of the included studies
revealed different percentages concerning the analyzed biases.
Low risks of bias have been found for random sequence
generation and allocation concealment. In 75% (6/8) of the
studies, a low risk of bias was determined. A total of 88% (7/8)
of the studies performed proper allocation concealment,
minimizing selection bias. The studies were inconsistent with
regard to performance and detection bias. In 63% (5/8) of the
studies, a low or high risk of bias could not be determined due
to missing information. This was also evident for the detection
bias, as the blinding of outcome assessment was often not
described. The risk of attrition bias was relatively low in the
studies (5/8, 63%). In contrast, the risk of other biases could
not be ruled out, as sample sizes, gender biases, or intervention
development for only 1 system software (either Android or iOS)
could bias the reported effects. Therefore, the percentage of
other biases was relatively high, accounting for 62.5% (5/8) of
the studies that had a high risk of bias. Comparing the results
of the quality assessment by Hailey et al [30] and the risk of
bias assessment, a good agreement was found. The overall
percentages are shown in Figure 2. Detailed bias characteristics
of the included studies can be obtained from Figure 3.
JMIR Mhealth Uhealth 2021 | vol. 9 | iss. 2 | e24703 | p. 9http://mhealth.jmir.org/2021/2/e24703/
(page number not for citation purposes)
Hrynyschyn & DockweilerJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Figure 2. Risk of bias graph.
Figure 3. Risk of bias summary.
Description of Patient Characteristics
The overall mean age of the included patients was relatively
similar. Only 1 study reported considerably lower ages in the
IG and CG [38]. The authors reported the mean age to be 24.76
years (SD 3.70) in the IG and 22.65 years (SD 2.42) in the CG.
The overall mean age of the patients in the IG ranged from 24.76
to 43.84 years (mean 35.99, SD 6.35; median 36.85) indicating
that the studies observed a relatively young population. The
patients in the CG were slightly younger than those in the IG.
The lowest age was reported to be 22.65 years, whereas the
highest age was reported to be 44.57 years (mean 35.36, SD
7.14; median 33.85). The study by Roepke et al [35] was the
only study that reported conventional levels of statistical
significance regarding age differences (F2,280=2.89; P=.06). The
other studies either did not conduct statistical inference or did
not report significant differences.
The included studies were highly heterogeneous regarding
gender distribution. All studies reported a higher percentage of
female patients participating than male patients. This was
evident for IG and CG. The most balanced gender distribution
for IG was found in the study by Ly et al [37]. They reported
that 66% (30/46) were female patients and 35% (16/46) were
male patients. The same study also reported the most balanced
gender distribution for CG, indicating that 75% (35/47) were
female and 26% (12/47) were male. In contrast, other studies
had female participant percentages between 80% and 90%
[34,36,39].
The observed patients in the included studies were moderately
depressed with respect to baseline PHQ-9 values. Only 5 of the
8 studies reported baseline PHQ-9 values [16,34,36,37,39]. The
PHQ-9 values ranged from 10.07 to 16.1 in the IG (mean 13.36,
SD 2.52; median 13.63) and 8.55 to 16.1 in the CG (mean 13.27,
SD 2.95; median 13.64). These mean PHQ-9 values indicate
that the observed population had moderate depression [40].
Three studies assessed baseline depression symptoms using the
BDI-II [33,37,38]. The results are comparable to the PHQ-9
values, indicating that the patients had moderate depression
symptoms [41]. The BDI-II values ranged from 22.65 to 28.96
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in the IG (mean 26.65, SD 3.48; median 28.35) and 25.59 to
32.33 in the CG (mean 28.41, SD 3.5; median 27.32). In contrast
to the studies with PHQ-9 measurement, the CG of the studies
with BDI-II reported higher values when compared with the
IG.
The participants were recruited from the general population.
Some studies also recruited patients from outpatient clinics
[36,38,39]. Dahne et al [30] recruited patients only from
outpatient clinics. Mostly, the recruitment strategies included
advertisements on the internet (eg, Craigslist) or social media
platforms (eg, Twitter). All studies excluded participants with
suicidal thoughts or beliefs. Furthermore, some studies excluded
participants who had different doses of antidepressants,
comorbidities, alcohol problems, or were already treated by
psychotherapy [34,37].
Implications for Depression Symptoms
Data regarding depression symptoms were good. All studies
investigated the effects on depression symptoms. However, the
reported results of these studies are inconsistent and do not
suggest clear implications for depression symptoms.
A total of 5 studies found that there was no significant difference
between the IG and CG. Arean et al [16] determined a PHQ-9
score decrease of 0.73 points for the total sample. However, the
models revealed no significant difference between the 2 IGs
when compared with the CG (β-coefficient −0.01; P=.90). This
was also evident in the mildly depressed subgroup analysis.
Other subgroup analysis revealed that there was a significant
difference for patients with a higher baseline depression at week
12 for the IG that received problem-solving therapy relative to
the CG (t201=−2.36; P=.02). Dahne et al [30,33] showed that
the between-group mean differences were not significantly
different across time points. This was found for IG versus CG
2 (the notations are based on the names used in Table 2; mean
difference −3.94; P=.18), IG versus CG 1 (mean difference
1.74; P=.55), and CG 1 versus CG 2 (mean difference −5.69;
P=.07). The only significant between-group difference was
observed in week 6, in which both IGs reported significantly
lower depressive symptoms compared with the treatment as
usual condition: IG versus CG 2 (mean difference −7.51; P=.02)
and CG 1 versus CG 2 (mean difference −7.68; P=.03). The
reported effect sizes were low, estimating Cohen d to be 0.33
for IG and 0.44 for CG 1. The study by Hur et al [38] was the
only study that estimated the effects between the IG and CG
using a nonparametric Wilcoxon rank-sum test. This test also
revealed no significant differences between intervention and
CG at follow-up (Z=−1.90; P=.06). Other studies conducted an
analysis of variance to estimate the differences between
intervention and control. Ly et al [37] determined an F1,171.81
value of 0.13 for BDI-II and F1,911.85=0.11 for PHQ-9, indicating
that there was no significant difference between the IG and CG
(P=.72 and .74, respectively). These results were supported by
Lüdtke et al [36] who estimated an F value of 0.173 for PHQ-9
scores with a P value of .68.
Three studies estimated the positive effect of smartphone-based
cognitive therapy for depression symptoms. Roepke et al [35]
determined depression symptoms using the Center for
Epidemiologic Studies Depression Scale and found that IG 1
significantly decreased symptoms relative to the waitlist CG
(t237=−2.80; P<.01). In addition, a significant decrease was also
found in IG 2, which applied a self-esteem and acceptance app
(t237=−3.73; P<.001). When both IGs were compared, there was
no significant difference between the groups (t237=0.82; P=.41),
indicating that the CBT app was not superior to the self-esteem
and acceptance app. The other 2 studies used the PHQ-9 to
estimate depression symptoms. Both studies conducted an
analysis of variance, which revealed significant differences.
Bakker et al [39] compared 3 different interventions with the
control condition. Only IG 2 and IG 3, which provided CBT
strategies and CBT, showed significant decreases in depression
symptoms. The decrease in symptoms was slightly higher in
IG 3 (F=4.24; P<.05). The analysis of variance of IG 2 also
revealed a significant F value of 4.39 (P<.05). In addition, the
effect sizes were small partial eta–squared=0.035 (IG 3) and
partial eta–squared=0.038 (IG 2). In contrast, IG 1 showed no
significant effects relative to waitlist CG (F=0.78; P>.05).
Stiles-Shields et al [34] estimated in a repeated-measures
ANOVA (analysis of variance) a higher eta-squared effect size
of 0.18 and a significant F6 value of 2.78 (P=.02), stating that
the PHQ-9 scores differed significantly between group
assignments. Post hoc analyses revealed that significant
differences occurred between the IG 2 and the control condition
(P=.03), but no significant differences were found between the
behavioral activation app intervention and the other 2 groups
(P>.2).
It was evident that the studies that compared a smartphone-based
therapy app with a waitlist CG revealed significant differences.
With the exception of the study by Lüdtke et al [36], all studies
with a waitlist CG showed significant differences. Other studies
that had active CGs that applied other smartphone-based therapy
formats or support between face-to-face sessions could not
establish the superiority of smartphone-based CBT [33,37].
Implications for Anxiety
Of the 8 studies, 4 reported effects on anxiety. Arean et al [16],
Dahne et al [33], Stiles-Shields et al [34], and Lüdtke et al [36]
reported no results for anxiety. Only 50% (4/8) of the studies
reported the desired outcome, and the results are inconsistent.
Therefore, a clear implication of smartphone-based CBT cannot
be drawn.
Two studies found no significant differences in the reduction
of anxiety between the IG and CG. Ly et al [37] tested the
reduction of anxiety by conducting an analysis of variance,
which revealed a nonsignificant F1,162.05 value of 0.34 (P=.56).
In addition, the effect sizes were particularly low, estimating
Cohen d to be 0.03 (95% CI −2.30-2.37). Similar results were
found in the study by Bakker et al [39] who used the Generalized
Anxiety Disorder Scale (7-item). Although all groups reported
a decrease in anxiety, the comparison of the 3 interventions
revealed no significant values in the analysis of variance, and
the eta-squared effect size was similarly low, ranging from 0.009
to 0.017.
The other 2 studies that reported anxiety as outcomes estimated
a significant difference between the groups. Hur et al [38] used
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the State-Trait Anxiety Inventory-X2 tool and reported a Z value
of −2.10 at follow-up in a nonparametric Wilcoxon rank-sum
test. This was significant with a P value of .035. Both groups
showed significantly decreased anxiety symptoms when baseline
assessment and follow-up were compared (IG: Z=−2.91; P=.004;
CG: Z=−2.51; P=.01). Another study, which reported significant
effects of smartphone-based CBT on the reduction of anxiety,
found that both IGs significantly declined anxiety relative to
the waitlist CG. The t test for IG 1 estimated a t236 ratio of −2.48,
which was highly significant (P=.01). IG 2, using a general
version focused on self-esteem and acceptance app, expected a
t236 ratio of −4.10, which was also highly significant (P<.001).
Alternatively, no significant differences were found between
both IGs. The estimated difference between the IGs was 1.06,
favoring the general version of the intervention (t237=0.82;
P=.41). Furthermore, IG 2 revealed a large effect size (Cohen
d 0.92), whereas IG 1 showed only a small effect size (Cohen
d 0.43), relative to the waitlist CG [35].
Implications for Self-Efficacy or Self-Esteem
A total of 50% (4/8) of the included studies assessed the effects
on self-efficacy or self-esteem. It was evident that different
studies had underlying concepts and definitions of the term
self-efficacy and self-esteem. Hur et al [38] and Lüdtke et al
[36] measured self-esteem using the RSES, which assesses
positive and negative feelings about the self as levels of
self-esteem. The other 2 studies used various instruments to
determine the associated outcomes of self-efficacy or
self-esteem. Bakker et al [39] focused on coping abilities
connected to self-efficacy and used the Coping Self-Efficacy
Scale. However, Roepke et al [35] focused more on general
self-efficacy, measuring how much people believe in achieving
their goals despite difficulties. Therefore, the New General
Self-Efficacy Scale was used.
Studies that used the RSES found no significant increase in
self-esteem between the IG and CG. In a nonparametric
Wilcoxon rank-sum test, Hur et al [38] estimated a Z value of
−0.75, which was not significant (P=.45). Similar to this study,
Lüdtke et al [36] conducted an F test, which was not significant
as well (F1,71=1.464; P=.23).
The other 2 studies found significant increases in IG relative to
the CG. IG 2 and IG 3 significantly increased self-efficacy (IG
2: F=4.86; P<.05; IG 3: F=14.95, P<.001). Furthermore, in
mediation analyses, self-efficacy was found to be a significant
mediator influencing anxiety, well-being, and depressive
symptoms (P<.05) [39]. This was also evident in the study by
Roepke et al [35]. IG 1 and IG 2 significantly increased
self-efficacy relative to the CG at posttest. IG 2, which
specifically focused on self-esteem, did not show higher
increases in self-esteem relative to IG 1.
To conclude the implications for self-efficacy and self-esteem,
inconsistent results were found. Due to the small number of
studies and different assessment instruments, the effects of
smartphone-based therapy on self-efficacy and self-esteem
cannot be clearly shown. Different concepts of self-efficacy and
self-esteem are present in the analyzed studies, which may have
influenced the results. Furthermore, 1 study showed that
self-efficacy was a significant mediator for depression
symptoms, anxiety, and well-being.
Implications for Quality of Life
Three studies reported that outcomes for quality of life were
increased by smartphone-based CBT. In all studies, it was
unclear if quality of life was measured in relation to health, as
the studies used the term Quality of life instead of health-related
quality of life. Due to the limited number of studies, it was not
possible to draw implications that support the hypothesis of an
increase in quality of life by applying smartphone-based CBT.
All 3 studies that directly measured quality of life could not
establish significant effects between the IG and CG. Hur et al
[38] reported a Z value of 1.19, which was not significant
(P=.23). In addition, the analysis of variance of Ly et al [37]
was also not significant (F1,165.17=1.06; P=.31). This was
supported by the results of Lüdtke et al [36], who also did not
find significant difference between the groups when analyzing
the variance (F1,70=0.041; P=.84).
Concepts and definitions of quality of life are quite diverse.
Therefore, there were 2 additional studies that reported subareas
of quality of life. For example, Bakker et al [39] used the term
well-being to describe quality of life. The authors showed that
there was a significant increase in well-being in patients with
depression that used IG 2 and IG 3 relative to the CG (IG 2:
F=11.0, P<.001; IG 3: F=9.47, P<.01). Beyond this, Roepke et
al [35] used the term life satisfaction and reported a significant
increase in IG 1 and IG 2 (IG 1: t236=3.55, P<.001; IG 2:
t236=2.71, P=.01). However, no significant difference was found
between the 2 IGs.
Concluding the results of the studies, there are no clear
implications concerning quality of life. Three studies that
measured quality of life with established instruments [36] found
no effects of smartphone-based therapy. Other studies that had
a broader definition of life satisfaction or well-being could report
effects. However, these aspects only used subareas of the
concept of quality of life.
Discussion
Principal Findings
In conclusion, the comparability of the studies is limited due to
various factors. This makes it difficult to interpret the obtained
results. Due to various approaches to smartphone-based CBT,
results differed between the studies. Significant differences were
found in gender distributions between the groups, which might
have biased the results. In addition, a lack of standardized
presentation of the investigated endpoints made it difficult to
generate clear implications. Although depression symptoms
were mostly assessed with PHQ-9 or BDI-II, other investigated
endpoints were assessed with different instruments, which made
the comparability difficult. This may be due to the different
objectives of the studies. For consistently reported endpoints,
such as depression symptoms, the obtained results contradicted
each other. Accordingly, no evident results could be found for
smartphone-based CBT among patients with depression.
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This systematic review has methodological limitations. This
concerns the development of the search syntax. For its
development, keywords and MeSH terms were used to identify
suitable studies. The keywords of the studies were integrated
into the search syntax for a larger number of hits. A complete
coverage of all relevant keywords could not be guaranteed,
which may have led to a bias in the study selection. The strength
of this review was the systematic approach and the predefined
procedure. To make the search procedure more comprehensible,
the search syntax is presented in Multimedia Appendix 1.
Further limitations exist in the selection of studies. Studies were
selected from the PubMed and Psyndex databases. Other
fee-based databases were not considered and may have led to
a selection bias. In addition, the 2 databases can be seen as the
most relevant databases for the underlying research question.
Furthermore, a selection bias can exist because of language.
Only German and English studies were selected.
In total, 8 studies were included in the systematic review. The
small number of studies made it difficult to prepare a funnel
plot. Therefore, no information can be provided on possible
publication biases. In addition, the included studies reported
small effect sizes, which do not lead to a large dispersion around
the no-effect line.
Finally, the use of the quality assessment tool must be reviewed
critically. Owing to the subjective assignment of points to study
design and performance, distortion cannot be excluded. To
control this, quality assessment was discussed between the 2
reviewers. However, it can be stated that the applied instrument
is reliable, as it has already been applied in several telemedical
studies. This also accounts for the risk of bias assessment. For
orientation, the Cochrane Handbook for Systematic Reviews
of Intervention (Version 5.1.0) was used. Imprecise reporting
of the included studies may have led to a different assessment
of the studies. To control for this judgment, the quality
assessment instrument and risk of bias tool were conducted
multiple times, and the results were discussed between the 2
reviewers. The vague reporting of the authors was labeled as
unclear risk of bias, as shown in Figure 3. However, comparing
the quality assessment tool with the risk of bias tool, a
concordance can be seen regarding the results.
The small number of included studies can be explained by the
selection of study designs. Only RCTs were included to
guarantee the highest evidence level. Therefore, this underlying
work is a systematic review with a high evidence level.
Furthermore, the included studies could report a high quality
with a mean score of 11.43 points (median 12 points), indicating
that the study design and performance of the RCTs were
sufficient.
The content of this review was prepared by a qualitative
synthesis of the study results. No statistical analysis of the
individual studies was performed with the aid of a forest plot
to evaluate the results. As a result, no meta-analysis was
performed, which weakens the explanatory power of the results.
The results of the review are based on the statistically
determined values of the included studies, which were
descriptively reported. A high heterogeneity between the studies
was the leading argument for not performing a meta-analysis.
Although the clinical heterogeneity was medium, the
methodological heterogeneity was high. The included studies
used different statistical tests to determine the effectiveness of
smartphone-based CBTs. Due to the small number of included
studies, a subgroup analysis was not considered to be useful.
The heterogeneity of studies can further be explained by the
research topic. Smartphone-based therapy is a relatively new
research topic; therefore, current evidence is limited. CBT, as
a profound treatment strategy, has experienced alterations and
divisions into smaller treatment sections (eg, mindfulness-based
therapy as a component of CBT). These alterations lead to an
imprecise use of the definition of CBT. To control this, a sharper
inclusion criterion in the beginning might have helped limit
clinical and methodological heterogeneity. However, the
observed heterogeneity between the studies is not unique to this
work because Firth et al [39] determined similar problems with
heterogeneity when evaluating the effectiveness of
smartphone-based interventions. As children and minorities
were excluded, the obtained results were not conclusive for
these groups.
Comparison With Prior Work
To place the obtained results in the scientific context, a
systematic review and meta-analysis of Firth et al [42] was
identified, which showed a significant reduction in depressive
symptoms when smartphone-based mental health interventions
were applied. In agreement with the results of this review, the
authors of the study only found small to medium effect sizes of
the intervention. These effect sizes differed when inactive or
active CGs were used for comparison. These results cannot be
supported by this review, but the statement is limited because
a meta-analysis was not conducted. Furthermore, this review
had a more detailed approach to mental health interventions.
The underlying review assessed the effectiveness of a
smartphone-based CBT. However, Firth et al [42] chose a
broader approach and included all studies that were classified
as a mental health intervention with no scope on specific
treatment strategies. This might be a reason why the authors
could include 18 studies, whereas this review only found 8
eligible studies. Many studies that were included by Firth et al
[42] were excluded in this review for a comprehensible reason.
The inclusion of the same studies showed that this review
identified the most relevant studies in the research area. Multiple
studies that were performed after 2017 were not included by
Firth et al [42]. Therefore, this review can be viewed as an
update of the effectiveness of smartphone-based therapy among
patients with depression. It should also be noted that this review
particularly assessed smartphone-based CBT approaches.
Another review by Bakker et al [43] formulated evidence-based
recommendations, which stated that CBT is a well-researched
therapeutic technique for depression. In particular, the
effectiveness of computerized CBT was proven by 2
meta-analyses [44,45]. However, recommendations that
smartphone-based CBT is effective cannot be supported by this
review. The results of this review are inconclusive for the
observed endpoints of depression, anxiety, self-efficacy or
self-esteem, and quality of life.
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It is apparent that evidence for smartphone-based CBT is
limited. Although the economic and public health importance
of depression is often mentioned, there is a lack of RCTs with
good quality. The effects of smartphone-based apps are
insufficiently analyzed. Therefore, there is need for further
research. Current research efforts are more focused on
determining the feasibility and moderators that are present when
applying smartphone-based CBT. These studies fail to determine
the effectiveness of technologies that are needed to build the
basis for discussions about integrating new treatment methods
in reimbursement systems.
The lack of high-quality studies can also be associated with
whether effectiveness can only be determined by conducting
RCTs. Recently, there has been a rising discussion about
alternative study designs that are more flexible than rigor RCT
and therefore more suitable for evaluating mHealth technologies
[46]. mHealth and other health technologies are more difficult
to evaluate than pharmaceutical products. The task of science
is to develop new methods and assessment tools that consistently
represent the effects of smartphone-based treatments. Efforts
toward a standardized reporting of results in the sense of
evidence-based medicine would facilitate the comparability and
the implementation of systematic reviews and meta-analyses.
Actions such as the development of consolidated standards of
reporting trials of electronic and mHealth apps and web-based
telehealth (CONSORT-EHEALTH) are appreciated and should
be recommended for researchers who conduct clinical trials
using mHealth technologies [47]. This would facilitate and
simplify the execution of systematic reviews to determine
evidence-based recommendations for digital health.
For clinical practice, it is crucial to answer the question of how
smartphone-based treatment approaches can be integrated into
the current routines. Due to legal limitations (eg, ban of remote
treatment in Germany), it is clear that these new treatment
approaches should add current care and not replace it. A good
combination of remote treatment and face-to-face consultation
can be considered the gold standard.
Smartphone-based therapy must not interfere with everyday
practice or be perceived as disturbing them. Here, technology
developers are called upon to develop such a technology for
practice. Further training courses for practitioners are of
particular importance with regard to the acceptance of
smartphone-based therapy.
mHealth interventions often face high attrition rates, which
hinders the practical use of those technologies. Therefore, it is
of major importance that mHealth interventions are designed
with a participatory approach. By integrating users, practitioners,
and developers, more effective interventions can be created that
are actually used in clinical practice. Concepts such as
human-centered design in health technology development should
be prioritized to provide digital public health interventions and
help patients with a high burden of disease [48,49]. As mHealth
interventions rely on user interaction and application, it is
important that potential users understand the concepts and
applications of smartphone-based therapy. Information and
exercises (eg, mood tracking or cognitive behavioral tasks) that
are not fully understood by its users lead to attrition.
Practitioners or caregivers are seen as being in a position to
provide training and introduction and to support the patient in
the process of use. In the beginning, this might be a hindering
factor for the practitioner to use smartphone-based therapy, but
the benefits could be long lasting and establish a shared-decision
partnership between the practitioner and the patient. It should
be noted that digital competence is always linked to literacy
and a certain degree of education. To provide smartphone-based
therapy to all population groups, a special focus should be placed
on minorities and population groups that face socioeconomical
disadvantages. Those population groups need major support
and training to ensure that they profit from mHealth
interventions.
Fields of action for policy are seen in the development of
mHealth structures. In this context, the GlobalStrategy for
Digital Health, published by the WHO in 2019, can be
acclaimed, as their aim is to apply digital health by a vision of
health for all. More precisely, the WHO emphasizes that digital
health adoption is a decision of the respective country, which
requires a unified strategy that integrates leadership, financial,
organizational, human, and technological resources. In addition,
the use of digital technologies is needed to support equity in
terms of access to care by being people-centered,
evidence-based, and ethically appropriate [50]. As mHealth
competences and socioeconomic determinants are not equally
distributed, people with a low socioeconomic status and low
competencies need to be supported more. Therefore, policy
makers should especially consider those aspects when creating
or passing new laws to establish mHealth structures. It is of
major importance that digital innovations do not widen the gap
of social disparity, which subsequently results in health inequity.
Transparency is an important aspect that empowers patients to
make their own decisions [51]. Especially in smartphone-based
therapy, it can be seen that the market of apps (eg, Appstore or
Android Store) is highly unregulated and policy makers are
required to develop regulatory instruments to ensure patients’
safety. By regulating the market, technological and scientific
innovation can be slowed down. However, it is mandatory that
users are able to fully understand whether the app is a medical
device or an unregulated app with no evidence-based
background [52,53]. Furthermore, the development and
functioning of apps is often compared with a blackbox because
data use and underlying mechanisms are often hidden by the
developers. This hinders transparency, as users should fully
understand and know what happens with their data. Open-source
projects can be a solution to empower users to understand the
mechanisms of mHealth. Through strong involvement of
organized interests in health care systems, policy makers must
ensure that all involved actors in ensuring care are committed
to adhere to the framework conditions. The General Data
Protection Regulation of the European Union that increases data
protection must also be considered in mHealth interventions
[54].
Other areas of responsibility, which need to be addressed by
policy makers, include financing issues of mHealth. Although
benefits of certain forms of mHealth apps have been proven,
the widespread implementation of the technology is failing due
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to financing problems. Financing of innovations as pilot studies
is not efficient in the long term. Accordingly, after successful
pilot studies, large-scale studies are needed, and the transfer to
standard care should be achieved without delay. The obligation
of policy makers is to sustainably fund these efforts to
modernize and digitalize health care [55].
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